ESMO-BC-I 2020 - ESMO Breast Cancer Annual Congress (Virtual Meeting)
May 23 - May 24, 2020 | BerlinGermany
LARVOL is not affiliated with ESMO Breast Cancer Annual Congress (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 87 abstracts linked to Trials
[VIRTUAL] GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer
[VIRTUAL] A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)
[VIRTUAL] Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
[VIRTUAL] Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
[VIRTUAL] The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
[VIRTUAL] Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)
[VIRTUAL] Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE
[VIRTUAL] Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)
[VIRTUAL] A single-arm, open label, single center study to evaluate the safety and clinical outcome of using FR-Mask in breast cancer patients with radiation-irritated skin
[VIRTUAL] Germline and somatic variants in DNA DMAGE repair (DDR) genes in patients with untreated, early-stage triple negative breast cancers (TNBC)
[VIRTUAL] Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC)
[VIRTUAL] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
[VIRTUAL] Prognostic value of the immune infiltration score in early breast cancer patients receiving dual HER2 blockade with trastuzumab and pertuzumab: An exploratory analysis of a randomized clinical trial
[VIRTUAL] Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)
[VIRTUAL] PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study